Izotropic Corporation
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. The company develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses offering high resolution, true 3D dedicated breast imaging with 360-degree image acquisition and can be used with or without injectable contrast. Izotropic Corporation … Read more
Izotropic Corporation (IZOZF) - Net Assets
Latest net assets as of October 2025: $-5.50 Million USD
Based on the latest financial reports, Izotropic Corporation (IZOZF) has net assets worth $-5.50 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($447.06K) and total liabilities ($5.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.50 Million |
| % of Total Assets | -1230.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | -207.56% |
| 10-Year Change | N/A |
| Growth Volatility | 248.53 |
Izotropic Corporation - Net Assets Trend (2017–2025)
This chart illustrates how Izotropic Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Izotropic Corporation (2017–2025)
The table below shows the annual net assets of Izotropic Corporation from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | $-4.86 Million | -26.33% |
| 2024-04-30 | $-3.85 Million | -25.13% |
| 2023-04-30 | $-3.07 Million | -720.57% |
| 2022-04-30 | $-374.59K | -108.29% |
| 2021-04-30 | $4.52 Million | +538.75% |
| 2020-04-30 | $707.22K | +123.21% |
| 2019-04-30 | $316.84K | -22.30% |
| 2018-04-30 | $407.76K | +730.52% |
| 2017-04-30 | $-64.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Izotropic Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2203860500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $17.28 Million | % |
| Total Equity | $-4.86 Million | 100.00% |
Izotropic Corporation Competitors by Market Cap
The table below lists competitors of Izotropic Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Opter AB
ST:OPTER
|
$13.55 Million |
|
LGMS Berhad
KLSE:0249
|
$13.55 Million |
|
Earth Tech Environment Public Company Limited
BK:ETC
|
$13.55 Million |
|
Isofol Medical AB
ST:ISOFOL
|
$13.56 Million |
|
Bayview Acquisition Corp Unit
NASDAQ:BAYAU
|
$13.54 Million |
|
Ozsu Balik Uretim A.S.
IS:OZSUB
|
$13.54 Million |
|
3P Learning Ltd
AU:3PL
|
$13.53 Million |
|
Principal Technologies Inc
V:PTEC
|
$13.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Izotropic Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,846,254 to -4,858,987, a change of -1,012,733.
- Net loss of 3,139,710 reduced equity.
- New share issuances of 920,000 increased equity.
- Other factors increased equity by 1,206,977.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.14 Million | -64.62% |
| Share Issuances | $920.00K | +18.93% |
| Other Changes | $1.21 Million | +24.84% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Izotropic Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-04-30 | $0.00 | $0.22 | x |
| 2018-04-30 | $0.02 | $0.22 | x |
| 2019-04-30 | $0.01 | $0.22 | x |
| 2020-04-30 | $0.02 | $0.22 | x |
| 2021-04-30 | $0.11 | $0.22 | x |
| 2022-04-30 | $-0.01 | $0.22 | x |
| 2023-04-30 | $-0.06 | $0.22 | x |
| 2024-04-30 | $-0.07 | $0.22 | x |
| 2025-04-30 | $-0.08 | $0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Izotropic Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-64.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-91.85K |
| 2018 | -179.06% | 0.00% | 0.00x | 1.21x | $-770.91K |
| 2019 | -125.78% | 0.00% | 0.00x | 1.07x | $-430.22K |
| 2020 | -163.43% | 0.00% | 0.00x | 1.10x | $-1.23 Million |
| 2021 | -110.16% | 0.00% | 0.00x | 1.04x | $-5.43 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.62 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.35 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.18 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.65 Million |
Industry Comparison
This section compares Izotropic Corporation's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Izotropic Corporation (IZOZF) | $-5.50 Million | 0.00% | N/A | $13.55 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |